2024
Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease.
Petrov J, Al-Bawardy B, Alzahrani R, Mohamed G, Fine S. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38595134, DOI: 10.1097/mcg.0000000000002003.Peer-Reviewed Original ResearchUstekinumab dose escalationDose-escalation groupInflammatory bowel diseaseDose escalationC-reactive proteinEndoscopic healingEscalation groupClinical remissionNormalization of C-reactive proteinSteroid-free clinical remissionBowel diseaseSerum C-reactive proteinNormalization of serum C-reactive proteinMaintenance of remissionReal-world cohortProportion of patientsUstekinumab doseMean hemoglobinBaseline albuminRetrospective studyUstekinumabMale sexMultivariate analysisPrimary outcomeSecondary outcomesLonger Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDiseaseUstekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024 PMID: 38300529, DOI: 10.1097/mcg.0000000000001978.Peer-Reviewed Original ResearchArea under the curveInflammatory bowel diseaseEndoscopic healingTrough levelsBowel diseaseAssociated with favorable outcomesUstekinumab trough levelsHighest area under the curveCohort of patientsTherapeutic drug monitoringClinical remissionCombination therapyMedian ageCRP normalizationRetrospective studyDrug levelsFavorable outcomeUstekinumabDrug monitoringPrimary outcomeSecondary outcomesCRPPatientsOutcomesHealing
2023
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssaysOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2022
Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes